Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.83 -3.37%

-$0.34 today

Market cap
$189.33M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.77M

Average 0.48M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$76.75M

FY 2025 · Annual

Investing Cash Flow

$63.41M

FY 2025 · Annual

Financing Cash Flow

$9,000.00

FY 2025 · Annual

-100.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.83M)(58.79M)(28.72M)(65.37M)(83.87M)
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
Deferred Income Tax00000
Stock-Based Compensation4.31M6.58M7.05M6.98M6.82M
Change in Working Capital33.41M(3.87M)(28.28M)(325K)(424K)
Accounts Receivables(468K)(57K)(1.23M)1.61M79K
Inventory00000
Accounts Payables(1.24M)190K(408K)519K(760K)
Other Working Capital35.13M(4M)(26.64M)(2.46M)257K
Other Non-Cash Items18.55M4.08M251K1.26M(1.88M)
Operating Cash Flow(15.3M)(50.83M)(47.43M)(55.03M)(76.75M)
Capital Expenditures(1.72M)(6.3M)(3.26M)(642K)(2.59M)
Acquisitions (Net)00000
Purchases of Investments00(49.52M)(176.17M)(44.88M)
Sales of Investments0026.8M56.35M110.87M
Other Investing Activities00000
Investing Cash Flow(1.72M)(6.3M)(25.98M)(120.46M)63.41M
Debt Repayment000(149K)(132K)
Common Stock Issued000166.51M371K
Common Stock Repurchased0(5K)(12K)(4.18M)0
Dividends Paid00000
Other Financing Activities(1.86M)(1.26M)24.4M51K(230K)
Financing Cash Flow152.75M(1.26M)24.39M162.23M9K
Effect of Forex Changes00000
Net Change in Cash135.73M(58.39M)(49.01M)(13.27M)(13.33M)
Free Cash Flow(17.03M)(57.13M)(50.69M)(55.67M)(79.34M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$83.9M
+ D&A$2.6M
+ Stock-Based Comp$6.8M
+ Deferred Tax$0
- Working Capital-$424.0K
- Other Non-Cash-$1.9M
= Operating Cash Flow-$76.8M
- Capex-$2.6M
= Free Cash Flow-$79.3M

Analysis

FY2025 free cash flow is -$79.3M. FCF conversion is 94.6% of net income. Operating cash flow was -$76.8M, with capex of -$2.6M. The largest bridge item is Stock-Based Comp at $6.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-K/A8-K/A filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
4Statement of changes in beneficial ownershipNov 3, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

Does ARTV generate free cash flow?

Artiva Biotherapeutics, Inc. (ARTV) generated -$79.34M of free cash flow in fiscal 2025.

How much operating cash flow does ARTV produce?

Operating cash flow was -$76.75M, before capital expenditures of $2.59M.